Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $119.91M | $120.79M | $113.83M | $147.79M | $130.46M | $114.61M | $105.56M | $113.42M |
| Cost of Revenue | $43.91M | $38.26M | $40.61M | $64.85M | $61.43M | $28.75M | $31.28M | $27.36M |
| Gross Profit | $76.00M | $82.53M | $73.22M | $82.94M | $69.03M | $85.86M | $74.28M | $86.06M |
| Gross Margin | 63.38% | 68.33% | 64.33% | 56.12% | 52.91% | 74.92% | 70.37% | 75.87% |
| Operating Expenses | $81.10M | $81.69M | $69.55M | $80.33M | $97.35M | $51.62M | $52.53M | $40.33M |
| Operating Income | $-5.10M | $844.00K | $3.67M | $2.62M | $-28.32M | $34.25M | $21.75M | $45.73M |
| Operating Margin | -4.25% | 0.70% | 3.22% | 1.77% | -21.71% | 29.88% | 20.60% | 40.32% |
| Net Income | $-56.38M | $-82.67M | $-14.86M | $4.13M | $-23.98M | $27.19M | $18.72M | $31.82M |
| Net Margin | -47.02% | -68.44% | -13.05% | 2.80% | -18.38% | 23.73% | 17.74% | 28.05% |
| EPS (Basic) | $-3.83 | $-5.64 | $-1.02 | $0.29 | $-1.69 | $1.93 | $1.30 | $2.18 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |